Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | GUCY1B2 | O75343 | 15/20 | 0.47 |
| ▸ | GUCY1A2 | P33402 | 15/20 | 0.47 |
| ▸ | GUCY1A1 | Q02108 | 15/20 | 0.47 |
| ▸ | GUCY1B1 | Q02153 | 15/20 | 0.47 |
| ▸ | REV1 | Q9UBZ9 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3239261 | 0.92 | GUCY1B2 (0.47) | RAB9ASMN1; SMN2GUCY1B2GUCY1A2GUCY1A1 | |
| SCHEMBL3233436 | 0.92 | FFAR4 (0.41) | RAB9ASMN1; SMN2GUCY1B2GUCY1A2GUCY1A1 | |
| SCHEMBL3228802 | 0.91 | SMN1; SMN2 (0.42) | RAB9ASMN1; SMN2GUCY1B2GUCY1A2GUCY1A1 | |
| SCHEMBL3231021 | 0.91 | SMN1; SMN2 (0.44) | RAB9ASMN1; SMN2GUCY1B2GUCY1A2GUCY1A1 | |
| SCHEMBL3234749 | 0.90 | GUCY1B2 (0.42) | RAB9ASMN1; SMN2GUCY1B2GUCY1A2GUCY1A1 | |
| SCHEMBL3230163 | 0.90 | GUCY1B2 (0.44) | RAB9ASMN1; SMN2GUCY1B2GUCY1A2GUCY1A1 | |
| SCHEMBL3230876 | 0.90 | GUCY1B2 (0.40) | RAB9ASMN1; SMN2GUCY1B2GUCY1A2GUCY1A1 | |
| SCHEMBL3235323 | 0.89 | PTGDR2 (0.42) | RAB9ASMN1; SMN2GUCY1B2GUCY1A2GUCY1A1 | |
| SCHEMBL3229980 | 0.89 | RAB9A (0.47) | RAB9ASMN1; SMN2GUCY1B2GUCY1A2GUCY1A1 | |
| SCHEMBL3233253 | 0.89 | RAB9A (0.47) | RAB9ASMN1; SMN2GUCY1B2GUCY1A2GUCY1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2594270-A2 | The use of sGC stimulators, sGC activators, alone and combinations with PDE5 inhibitors for the treatment of systemic sclerosis (SSc) | BIP Patents (DE) | 2013-05-22 | — | — | EP | claimed |
| WO-2010015652-A2 | THIAZOLE COMPOUNDS AS ACTIVATORS OF SOLUBLE GUANYLATE CYCLASE | SMITHKLINE BEECHAM CORPORATION (US) | 2010-02-11 | — | — | WO | claimed |
| EP-2594270-A2 | The use of sGC stimulators, sGC activators, alone and combinations with PDE5 inhibitors for the treatment of systemic sclerosis (SSc) | BIP Patents (DE) | 2013-05-22 | — | — | EP | disclosed |
| WO-2010015652-A2 | THIAZOLE COMPOUNDS AS ACTIVATORS OF SOLUBLE GUANYLATE CYCLASE | SMITHKLINE BEECHAM CORPORATION (US) | 2010-02-11 | — | — | WO | disclosed |